$28.53▴ 2.59%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-121.54MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Lowdebt to assets
Strong
Very low debt relative to its asset base.
More coming: dilution / share-count creep.
✦ The read
Maze Therapeutics, Inc. is pre-profit. It is still burning cash while pre-profit. Very low debt relative to its asset base.
Key numbers
Valuation
EPS (TTM)$-2.48
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-612.7%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$20.00M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.